Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 354


Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial.

Winhusen TM, Somoza EC, Brigham GS, Liu DS, Green CA, Covey LS, Croghan IT, Adler LA, Weiss RD, Leimberger JD, Lewis DF, Dorer EM.

J Clin Psychiatry. 2010 Dec;71(12):1680-8. doi: 10.4088/JCP.09m05089gry.


Treating nicotine dependence by targeting attention-deficit/ hyperactivity disorder (ADHD) with OROS methylphenidate: the role of baseline ADHD severity and treatment response.

Nunes EV, Covey LS, Brigham G, Hu MC, Levin FR, Somoza EC, Winhusen TM.

J Clin Psychiatry. 2013 Oct;74(10):983-90. doi: 10.4088/JCP.12m08155.


Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.

Riggs PD, Winhusen T, Davies RD, Leimberger JD, Mikulich-Gilbertson S, Klein C, Macdonald M, Lohman M, Bailey GL, Haynes L, Jaffee WB, Haminton N, Hodgkins C, Whitmore E, Trello-Rishel K, Tamm L, Acosta MC, Royer-Malvestuto C, Subramaniam G, Fishman M, Holmes BW, Kaye ME, Vargo MA, Woody GE, Nunes EV, Liu D.

J Am Acad Child Adolesc Psychiatry. 2011 Sep;50(9):903-14. doi: 10.1016/j.jaac.2011.06.010.


Divergence by ADHD subtype in smoking cessation response to OROS-methylphenidate.

Covey LS, Hu MC, Weissman J, Croghan I, Adler L, Winhusen T.

Nicotine Tob Res. 2011 Oct;13(10):1003-8. doi: 10.1093/ntr/ntr087.


A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.

Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR.

CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6.


Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.

Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C; 31001074-ATT2001 Study Investigators..

CNS Drugs. 2012 May 1;26(5):421-34. doi: 10.2165/11631990-000000000-00000.


OROS-methylphenidate or placebo for adult smokers with attention deficit hyperactivity disorder: racial/ethnic differences.

Covey LS, Hu MC, Winhusen T, Weissman J, Berlin I, Nunes EV.

Drug Alcohol Depend. 2010 Jul 1;110(1-2):156-9. doi: 10.1016/j.drugalcdep.2010.02.002.


An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder.

Covey LS, Hu MC, Green CA, Brigham G, Hurt RD, Adler L, Winhusen T.

Am J Drug Alcohol Abuse. 2011 Sep;37(5):392-9. doi: 10.3109/00952990.2011.596979.


Anxiety and Depressed Mood Decline Following Smoking Abstinence in Adult Smokers with Attention Deficit Hyperactivity Disorder.

Covey LS, Hu MC, Winhusen T, Lima J, Berlin I, Nunes E.

J Subst Abuse Treat. 2015 Dec;59:104-8. doi: 10.1016/j.jsat.2015.07.004.


A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.

Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T.

Biol Psychiatry. 2006 May 1;59(9):829-35. Erratum in: Biol Psychiatry. 2007 Jun 15;61(12):1402.


A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder.

Rösler M, Fischer R, Ammer R, Ose C, Retz W.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):120-9. doi: 10.1007/s00406-008-0845-4. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009 Sep;259(6):368.


Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.

Chou WJ, Chen SJ, Chen YS, Liang HY, Lin CC, Tang CS, Huang YS, Yeh CB, Chou MC, Lin DY, Hou PH, Wu YY, Liu HJ, Huang YF, Hwang KL, Chan CH, Pan CH, Chang HL, Huang CF, Hsu JW.

J Child Adolesc Psychopharmacol. 2012 Jun;22(3):215-25. doi: 10.1089/cap.2011.0006.


OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.

Bron TI, Bijlenga D, Boonstra AM, Breuk M, Pardoen WF, Beekman AT, Kooij JJ.

Eur Neuropsychopharmacol. 2014 Apr;24(4):519-28. doi: 10.1016/j.euroneuro.2014.01.007.


Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial.

Hurt RD, Ebbert JO, Croghan IT, Schroeder DR, Sood A, Hays JT.

J Negat Results Biomed. 2011 Jan 28;10:1. doi: 10.1186/1477-5751-10-1.


Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.

Huss M, Ginsberg Y, Tvedten T, Arngrim T, Philipsen A, Carter K, Chen CW, Kumar V.

Adv Ther. 2014 Jan;31(1):44-65. doi: 10.1007/s12325-013-0085-5.


A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.

Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD.

J Clin Psychiatry. 2008 Jan;69(1):149-59. Erratum in: J Clin Psychiatry. 2008 Feb;69(2):329.


Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.

Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS.

J Clin Psychiatry. 2008 Dec;69(12):1938-47.


Supplemental Content

Support Center